THERAVANCE BIOPHARMA,INC. (NASDAQ:TBPH) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
(a) The 2017 Annual General Meeting of Shareholders (the Annual
Meeting) was held on May17, 2017.
(b) Shareholders holding 51,198,276 shares of capital stock,
representing 96.14% of the total number of shares outstanding and
entitled to vote at the Annual Meeting, were present in person or
by proxy at the Annual Meeting.
The nominees listed below were elected ClassIII members of the
Board of Directors with the respective numbers of shares voted
set forth opposite their names:
|
Nominees |
|
For |
|
Against |
|
Abstain |
|
Broker Non-Votes |
|
|
Dean J. Mitchell |
47,572,089 |
477,859 |
15,469 |
3,132,859 |
|||||
|
Percentage of Shares Voted |
98.98% |
0.99% |
0.03% |
|
|||||
|
Peter S. Ringrose |
47,555,620 |
503,595 |
6,202 |
3,132,859 |
|||||
|
Percentage of Shares Voted |
98.94% |
1.05% |
0.01% |
|
|||||
|
George M. Whitesides |
47,555,565 |
503,650 |
6,202 |
3,132,859 |
|||||
|
Percentage of Shares Voted |
98.94% |
1.05% |
0.01% |
|
|||||
|
William D. Young |
46,785,429 |
1,273,786 |
6,202 |
3,132,859 |
|||||
|
Percentage of Shares Voted |
97.34% |
2.65% |
0.01% |
|
The shareholders ratified the selection by the Audit Committee of
the Board of Directors of Ernst Young LLP as the Companys
independent registered public accounting firm for the fiscal year
ending December31, 2017. The voting results are set forth below:
|
|
For |
|
Against |
|
Abstain |
|
BrokerNon- Votes |
|
|
|
Number of Shares Voted |
51,056,713 |
97,967 |
43,596 |
|
|||||
|
Percentage of Shares Voted |
99.72% |
0.19% |
0.09% |
|
The shareholders approved a non-binding advisory resolution
regarding executive compensation. The voting results are set
forth below:
|
|
For |
|
Against |
|
Abstain |
|
Broker Non-Votes |
|
|
|
Number of Shares Voted |
46,846,621 |
1,072,055 |
146,741 |
3,132,859 |
|||||
|
Percentage of Shares Voted |
97.46% |
2.23% |
0.31% |
|
The shareholders voted on a non-binding advisory resolution
regarding the frequency of advisory shareholder votes on
executive compensation, with a frequency of every 3 years being
approved by the shareholders. The voting results are set forth
below:
|
|
1Year |
|
2Years |
|
3Years |
|
Abstain |
|
Broker Non-Votes |
|
Uncast |
|
|
|
Number of Shares Voted |
17,540,866 |
110,942 |
30,152,759 |
249,790 |
3,132,860 |
11,059 |
|||||||
|
Percentage of Shares Voted |
36.50% |
0.23% |
62.75% |
0.52% |
|
|
In light of this vote, Theravance Biopharma intends to include
an advisory shareholder vote on the compensation of executives
in its proxy materials every 3 years, until the next advisory
vote on the frequency of shareholder votes on the compensation
of executives scheduled to occur at the Companys 2023 Annual
General Meeting of Shareholders.
For more information about the foregoing proposals, see
Theravance Biopharma,Inc.s definitive proxy statement on
Schedule 14A filed with the United States Securities and
Exchange Commission on April11, 2017.
About THERAVANCE BIOPHARMA, INC. (NASDAQ:TBPH)
Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases. THERAVANCE BIOPHARMA, INC. (NASDAQ:TBPH) Recent Trading Information
THERAVANCE BIOPHARMA, INC. (NASDAQ:TBPH) closed its last trading session up +0.04 at 36.38 with 246,042 shares trading hands.
